by Fred Dumais | Sep 13, 2023 | News Release
Seventh consecutive quarter of revenue growth at $14.1 million in Q3-23, up 132% over Q3-22. Physicians prescribing Enerzair and Atectura reached 2,503 at the end of Q3-23, representing a 23% increase from the prior quarter and a 221% rise year-over-year Total...
by Fred Dumais | Sep 7, 2023 | Communiqué de presse
MONTRÉAL (QUÉBEC), le 7 septembre 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd’hui qu’elle divulguera ses résultats financiers...
by Fred Dumais | Sep 7, 2023 | News Release
MONTREAL, QUEBEC , September 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2023...
by Fred Dumais | Aug 31, 2023 | Communiqué de presse
3,92 millions $ provenant d’un placement privé sans intermédiaire, et 0,58 million $ provenant d’un prêt d’un initié Investissement Québec et les initiés investissent chacun 2,0 millions $ Les produits du financement serviront à renforcer le fonds de...
by Fred Dumais | Aug 31, 2023 | News Release
$3.92 million raised from non-brokered private placement offering, and $0.58 million from insider loan Investissement Québec and insiders each invest $2.0 million Proceeds from the financing to be used to strengthen working capital and support ongoing growth...
